Orient EuroPharma Balance Sheet Health
Financial Health criteria checks 1/6
Orient EuroPharma has a total shareholder equity of NT$5.9B and total debt of NT$4.6B, which brings its debt-to-equity ratio to 77.8%. Its total assets and total liabilities are NT$12.3B and NT$6.5B respectively. Orient EuroPharma's EBIT is NT$118.7M making its interest coverage ratio 2.3. It has cash and short-term investments of NT$1.5B.
Key information
77.8%
Debt to equity ratio
NT$4.58b
Debt
| Interest coverage ratio | 2.3x |
| Cash | NT$1.55b |
| Equity | NT$5.88b |
| Total liabilities | NT$6.45b |
| Total assets | NT$12.33b |
Recent financial health updates
Here's Why Orient EuroPharma (GTSM:4120) Has A Meaningful Debt Burden
Apr 04
We Think Orient EuroPharma (GTSM:4120) Can Stay On Top Of Its Debt
Jan 04
Recent updates
Here's Why Orient EuroPharma (GTSM:4120) Has A Meaningful Debt Burden
Apr 04Is Orient EuroPharma Co., Ltd.'s (GTSM:4120) 3.3% Dividend Worth Your Time?
Mar 04A Look At Orient EuroPharma's (GTSM:4120) Share Price Returns
Feb 10Is Orient EuroPharma Co., Ltd.'s (GTSM:4120) Recent Performancer Underpinned By Weak Financials?
Jan 22We Think Orient EuroPharma (GTSM:4120) Can Stay On Top Of Its Debt
Jan 04A Look At The Fair Value Of Orient EuroPharma Co., Ltd. (GTSM:4120)
Dec 17Are Dividend Investors Getting More Than They Bargained For With Orient EuroPharma Co., Ltd.'s (GTSM:4120) Dividend?
Nov 29Financial Position Analysis
Short Term Liabilities: 4120's short term assets (NT$3.9B) do not cover its short term liabilities (NT$3.9B).
Long Term Liabilities: 4120's short term assets (NT$3.9B) exceed its long term liabilities (NT$2.5B).
Debt to Equity History and Analysis
Debt Level: 4120's net debt to equity ratio (51.5%) is considered high.
Reducing Debt: 4120's debt to equity ratio has increased from 41.8% to 77.8% over the past 5 years.
Debt Coverage: 4120's debt is not well covered by operating cash flow (0.4%).
Interest Coverage: 4120's interest payments on its debt are not well covered by EBIT (2.3x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 07:03 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Orient EuroPharma Co., Ltd. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xiaowei Huang | Masterlink Securities Corp. |